Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Biallelic antigen escape may be a mechanism of resistance to anti-CD38 antibodies; L153H and C275Y decreased binding affinity and ADCC of daratumumab and isatuximab, while a 3rd, R140G, conferred selective resistance to dara only.”
Title: Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma
Authors: Benjamin T. Diamond, Linda B Baughn, Mansour Poorebrahim, Alexandra M Poos, Holly Lee, Marcella Kaddoura, J Erin Wiedmeier-Nutor, Michael A. Durante, Gregory E Otteson, Dragan Jevremovic, Hongwei Tang, Stefan Fröhling, Marc-Andrea Baertsch, Marios Papadimitriou, Bachisio Ziccheddu, Tomas Jelínek, Cendrine Lemoine, Alexey Rak, Damian J Green, Carl Ola Landgren, Paola Neri, Peter Leif Bergsagel, Esteban Braggio, Shaji K Kumar, Marc S. Raab, Rafael Fonseca, Nizar Bahlis, Niels Weinhold, Francesco Maura.
You can read the Full Article in Blood.
More posts featuring Robert Orlowski.
